Gastroparesis primary prevention: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) No edit summary |
|||
| (7 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Effective measures for the primary prevention of gastroparesis include strict [[glycemic control]], [[Nutritional Therapy in Diabetes|nutritional therapies]], having frequent, small meals that are low in [[fat]] and [[Dietary fiber|fiber]], [[alcohol]] and [[smoking cessation]], regular [[exercise]] and avoidance of [[medications]] that impair gastric motility. | |||
==Primary Prevention== | ==Primary Prevention== | ||
Effective measures for the primary prevention of gastroparesis include:<ref name="pmid25874755">{{cite journal |vauthors=Stein B, Everhart KK, Lacy BE |title=Gastroparesis: A Review of Current Diagnosis and Treatment Options |journal=J. Clin. Gastroenterol. |volume=49 |issue=7 |pages=550–8 |year=2015 |pmid=25874755 |doi=10.1097/MCG.0000000000000320 |url=}}</ref><ref name="pmid8855743">{{cite journal |vauthors=Fontana RJ, Barnett JL |title=Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review |journal=Am. J. Gastroenterol. |volume=91 |issue=10 |pages=2174–8 |year=1996 |pmid=8855743 |doi= |url=}}</ref> | |||
*Strict [[glycemic control]] | |||
*Maintaining a proper [[Diet (nutrition)|dietary]] and [[Nutritional Therapy in Diabetes|nutritional therapies]] by working with a registered dietician | |||
*Having frequent, small meals that are low in [[fat]] and [[Dietary fiber|fiber]] | |||
**[[Fat]], [[Dietary fiber|fiber]], and large meals can delay stomach emptying and worsen symptoms | |||
*Keeping hydrated by drinking adequate amounts of water | |||
*[[Alcohol]] and [[smoking cessation]] | |||
*[[Physical exercise|Regular exercise]] | |||
*Medications that impair gastric motility has to be stopped or dosage must be adjusted according to patients needs:<ref name="pmid8965152">{{cite journal |vauthors=Maurer AH, Krevsky B, Knight LC, Brown K |title=Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy |journal=J. Nucl. Med. |volume=37 |issue=5 |pages=818–22 |year=1996 |pmid=8965152 |doi= |url=}}</ref> | |||
**[[Anticholinergics|Anticholinergic agents]] | |||
**[[GLP-1|GLP-1 analogs]] | |||
**[[Opiates]] | |||
==References== | ==References== | ||
Latest revision as of 16:25, 20 February 2018
|
Gastroparesis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gastroparesis primary prevention On the Web |
|
American Roentgen Ray Society Images of Gastroparesis primary prevention |
|
Risk calculators and risk factors for Gastroparesis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Effective measures for the primary prevention of gastroparesis include strict glycemic control, nutritional therapies, having frequent, small meals that are low in fat and fiber, alcohol and smoking cessation, regular exercise and avoidance of medications that impair gastric motility.
Primary Prevention
Effective measures for the primary prevention of gastroparesis include:[1][2]
- Strict glycemic control
- Maintaining a proper dietary and nutritional therapies by working with a registered dietician
- Having frequent, small meals that are low in fat and fiber
- Keeping hydrated by drinking adequate amounts of water
- Alcohol and smoking cessation
- Regular exercise
- Medications that impair gastric motility has to be stopped or dosage must be adjusted according to patients needs:[3]
References
- ↑ Stein B, Everhart KK, Lacy BE (2015). "Gastroparesis: A Review of Current Diagnosis and Treatment Options". J. Clin. Gastroenterol. 49 (7): 550–8. doi:10.1097/MCG.0000000000000320. PMID 25874755.
- ↑ Fontana RJ, Barnett JL (1996). "Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review". Am. J. Gastroenterol. 91 (10): 2174–8. PMID 8855743.
- ↑ Maurer AH, Krevsky B, Knight LC, Brown K (1996). "Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy". J. Nucl. Med. 37 (5): 818–22. PMID 8965152.